MTM Laboratories Planning FDA Filings for Cervical Disease Tests | GenomeWeb

By Tony Fong

NEW YORK (GenomeWeb News) – Seeking to capitalize on what MTM Laboratories' CEO calls the "next-generation technology beyond HPV testing," the German diagnostics firm plans to file for regulatory approval in the US in the coming months for its assay for high-grade cervical disease.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: transcriptional and translational study of human cytomegalovirus interactions with host cells, spider web DNA study, and more.

The New York Stem Cell Foundation signs a lease for a new space.

Researchers gear up for an international meeting to discuss the ethics of gene editing.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.